A retrospective study among patients with hereditary breast and ovarian cancer with no pathogenic BRCA mutations on initial testing, identified pathogenic/likely pathogenic mutations in genes like PALB2, BRIP1, BARD1, and RAD50 in addition to VUS in TP53, CHEK2, and CDH1 genes [10]. This evidence concerns the gene TP53 and ovarian carcinoma.